,0,1,2,3,4,5,6
0,,Accession ID: NGSO-221209001,,,,,Page 3 of 76
1,,"Patient Name: LAN ZHENG,MEI-CHAN",,,,,
2,,Diagnosis: gastric cancer,,,,,
3,YOURLAB,,,,,,
4,,,,Approved Therapies,,,
5,,,,,Associated With,Clinical,
6,Gene/Variant,Allelic Fraction,Gastric Cancer,Other Indications,Resistance,Trials,
7,MRE11,50.0% (of 229,,,,2,
8,c.689C>T,reads),,,,,
9,p.P230L,,,,,,
10,g.94471730G>A,,,,,,
11,Tier 2C,,,,,,
12,Likely Pathogenic,,,,,,
13,POLE,2.88% (of 139 reads),trifluridine,cladribine,,,
14,p.V1446fs*3,,,,,clofarabine,
15,g.132643513_132643,,,cytarabine,,,
16,514de|CA,Tier 2C,,,,daunorubicin,
17,Tier 2C,,,,,,
18,Pathogenic,,,,,,
19,RNF43,7.71% (of 441 reads),,,,,
20,c.813_825de|GTGTG,,,,,,
21,CCATCTGT,,,,,,
22,p.C272fs*143,,,,,,
23,g.58360807_583608,,,,,,
24,19delACAGATGGCA,,,,,,
25,CAC,,,,,,
26,Tier 2C,,,,,,
27,Likely Pathogenic,,,,,,
28,TP53,8.13%(of246 reads),,acalabrutinib,chlorambucil,2,
29,c.743G>A,,,acalabrutinib,fludarabine,,
30,p.R248Q,,,/obinutuzumab,,,
31,g.7674220C>T,,,,lenalidomide,,
32,Tier 2C,,,alemtuzumab,rituximab,,
33,Pathogenic,,,alemtuzumab,,,
34,,,,/rituximab,,,
35,,,,bortezomib,,,
36,,,,/rituximab,,,
37,,,,decitabine,,,
38,,,,duvelisib,,,
39,,,,fludarabine,,,
40,,,,phosphate,,,
41,,,,ibrutinib,,,
42,,,,idelalisib,,,
43,,,,idelalisib,,,
44,,,,/rituximab,,,
45,,,,lenalidomide,,,
